A solid tumor next-generation sequencing assay for biomarker analysis

The Oncomine™ Focus Assay is a targeted, multi-biomarker assay that  enables you to target hotspots, SNVs, indels, CNVs, and gene fusions  from DNA and RNA in a single workflow.

Designed for clinical and translational cancer research, the Oncomine  Focus Assay leverages Ion AmpliSeq™ technology to enable robust  results, low input amounts, and analysis of low quality samples, and is  compatible with FFPE fine needle aspirates and core needle biopsies.

• Simultaneous detection of hundreds of variants across 52 genes relevant to solid tumors
• Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA or RNA in a single workflow
• Includes solid tumor genes targeted by on-market oncology drugs and published evidence
• Content driven by the Oncomine™ Knowledgebase, which includes content aligned to approved therapies and indications

• Reproducible and sensitive detection of variants across multiple cancer types
• Compatible with as little as 10 ng sample, including FFPE fine needle biopsies and core needle aspirates
• Enables results from up to 6 samples per run for DNA and RNA in a single workflow
• NGS results in days rather than weeks, leveraging Ion Torrent™  sequencing technology and the Ion S5™ System or the Ion PGM™ System
• Includes Ion Select consumables and reagents manufactured to rigorous standards in our ISO 13485-compliant facility